스트로 바이오파마(STRO)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $15.24 (-1.55%), 시가총액 $0.52B, 52주 최저~최고 $0.68 ~ $40.91.
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II
스트로 바이오파마의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
스트로 바이오파마의 현재 주가는 $15.24 (-1.55%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
스트로 바이오파마의 시가총액은 약 $0.52B입니다.
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein syn